Immunome Inc. (IMNM)

Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...

The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome to Present at Upcoming Investor Conferences.

Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago.

The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...

Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The comp...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...